Stock ALLR ALLARITY THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Allarity Therapeutics, Inc. Nasdaq Stockholm

Equities

ALLR

US0167441049

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
AQ
Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
AQ
Allarity Therapeutics, Inc.' Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
CI
Allarity Therapeutics, Inc. Concludes Its Phase 2 Clinical Trial
CI
Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
AQ
Allarity Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances
AQ
Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
AQ
Allarity Therapeutics Says Stockholders' Equity 'Significantly' Exceeds Nasdaq's $2.5 Million Minimum Rule
MT
Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
AQ
Wall Street Set to Open Higher Thursday After Fed Holds Rate Steady, Jobless Claims Lower Than Expected
MT
Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
AQ
Allarity Therapeutics, Inc. Announces Early Discontinuation of Its Phase 2 Clinical Trial of Stenoparib
CI
Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
AQ
Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
AQ
Top Premarket Gainers
MT
Top Premarket Gainers
MT
Allarity Therapeutics to Implement 1-for-20 Reverse Stock Split
MT
Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
AQ
Transcript : Allarity Therapeutics, Inc. - Shareholder/Analyst Call
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALLR Stock
  4. ALLR Stock
  5. News Allarity Therapeutics, Inc.